Myomo (NYSEAMERICAN:MYO)’s share price traded down 0.6% during mid-day trading on Wednesday . The stock traded as low as $3.46 and last traded at $3.55. 2,564 shares were traded during mid-day trading, a decline of 100% from the average session volume of 760,092 shares. The stock had previously closed at $3.53.

Several equities analysts have recently issued reports on the company. Roth Capital set a $7.00 price target on Myomo and gave the stock a “buy” rating in a research report on Thursday, May 10th. HC Wainwright set a $12.00 price target on Myomo and gave the stock a “buy” rating in a research report on Thursday, May 10th. Finally, Zacks Investment Research lowered Myomo from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th.

Myomo (NYSEAMERICAN:MYO) last posted its quarterly earnings results on Wednesday, March 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.08. The firm had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.35 million. Myomo had a negative return on equity of 155.42% and a negative net margin of 257.70%.

Several institutional investors and hedge funds have recently bought and sold shares of MYO. A.R.T. Advisors LLC purchased a new position in shares of Myomo in the 1st quarter worth about $277,000. Hudson Bay Capital Management LP bought a new stake in Myomo in the 4th quarter worth about $294,000. Sequoia Financial Advisors LLC bought a new stake in Myomo in the 4th quarter worth about $257,000. Virtu Financial LLC bought a new stake in Myomo in the 4th quarter worth about $124,000. Finally, Citadel Advisors LLC increased its holdings in Myomo by 243.9% in the 1st quarter. Citadel Advisors LLC now owns 40,861 shares of the company’s stock worth $121,000 after buying an additional 28,981 shares in the last quarter.

Myomo Company Profile

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.